TRAVERE THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
TRAVERE THERAPEUTICS, INC. (TVTX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $29.86 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2022-02-24
- TRAVERE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2021 was $29.86M, a 31.36% increase from fiscal 2020.
- TRAVERE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2020 was $22.73M, a 11.09% increase from fiscal 2019.
- TRAVERE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2019 was $20.46M, a 4.97% increase from fiscal 2018.
- TRAVERE THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $19.49M, a 26.84% decline from fiscal 2017.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|
| 2021-12-31 | $29.86M 10-K · filed 2022-02-24 |
| 2020-12-31 | $22.73M 10-K · filed 2022-02-24 |
| 2019-12-31 | $20.46M 10-K · filed 2022-02-24 |
| 2018-12-31 | $19.49M 10-K · filed 2021-03-01 |
| 2017-12-31 | $26.64M 10-K · filed 2020-02-24 |
| 2012-12-31 | $4.40M 10-K/A · filed 2015-07-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |